Pharma News

Amgen announced the European Commission (EC) granted marketing authorization for Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Kyprolis is the first irreversible proteasome inhibitor approved in the European Union (EU) for use in combination treatment of patients with relapsed multiple myeloma

AstraZeneca, a global, innovation-driven biopharmaceutical business, announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical Campus. It will screen around 2 million chemical structures per target to find new compounds for disease targets.

Following the Rs.640-crore class action suit filed by the government against Nestle India, the apex consumer court on Tuesday said "unending testing of Maggi samples cannot go on".

China's plastic surgery industry is set to become the world's third largest by the end of this year with a valuation of 400 billion yuan ($62.6 billion) and is expected to double in size by 2019.

Taking vitamin D supplements does not reduce the number or severity of cold in asthma patients, suggests new research.

Prescribing antibiotic doses once or twice a week for tuberculosis (TB) treatment are more likely to lead to drug resistant strains than daily antibiotic regimens, new research has found.

Researchers have discovered a compound that accelerates diabetic wound healing, which may open the door to new treatment strategies.

Vital Therapies Inc, a biotherapeutic company developing ELAD, a cell-based therapy targeting the treatment of liver failure, announced that it has received written responses from the US FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial.

Eli Lilly and Company and Merck  known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA® (pemetrexed for injection) and Merck's KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed.

[adsense:336x280:8701650588]

In one of the biggest deals in the medical world, US-based global drug major Pfizer Inc announced acquiring leading Irish pharma firm Allergan plc for a whopping $160 billion.